Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × Unilateral HER2 Positive Breast Cancer × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1272 Carcinoma, Non-Small-Cell Lung 920 Prostatic Neoplasms 725 Neoplasms 626 Multiple Myeloma 547 Lymphoma 539 Colorectal Neoplasms 525 Lung Neoplasms 516 Leukemia 496 Leukemia, Myeloid, Acute 472 Neoplasm Metastasis 466 Melanoma 424 Lymphoma, Non-Hodgkin 416 Ovarian Neoplasms 415 Leukemia, Lymphocytic, Chronic, B-Cell 385 Pancreatic Neoplasms 370 Recurrence 333 Precursor Cell Lymphoblastic Leukemia-Lymphoma 327 Head and Neck Neoplasms 301 Lymphoma, Large B-Cell, Diffuse 293 Glioblastoma 292 Myelodysplastic Syndromes 287 Lymphoma, Follicular 285 Brain Neoplasms 285 Stomach Neoplasms 277 Carcinoma, Renal Cell 268 Hodgkin Disease 260 Rectal Neoplasms 255 Carcinoma, Hepatocellular 255 Sarcoma 248

Interventions

Trastuzumab 1 Paclitaxel 1 Epirubicin 1 Cyclophosphamide 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01594177 2014-03-13

DAFNE

GBG Forschungs GmbH

Phase 2 Completed

Unilateral HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡